某院重组人脑利钠肽药物利用评价标准的建立与应用  

Establishment and application of evaluation criteria for the utilization of recombinant human brain natriuretic peptide in a hospital

作　　者：王栓 齐腊梅[1] 黄灿[1] WANG Shuan;QI Lamei;HUANG Can(Department of Pharmaceutical Administration,Anqing Municipal Hospital,Anqing 246000,China)

机构地区：[1]安庆市立医院药事管理科,安庆246000

出　　处：《中国临床药学杂志》2023年第11期807-813,共7页Chinese Journal of Clinical Pharmacy

基　　金：中华国际医学交流基金会临床药学专项基金(编号Z-2021-46-2101)

摘　　要：目的建立重组人脑利钠肽药物利用评价(DUE)标准,评价其临床使用的合理性和规范性,为临床合理用药提供参考。方法参考药品说明书、相关指南和专家共识建立重组人脑利钠肽DUE标准,依据建立的DUE标准评价2022年9-11月重组人脑利钠肽使用的合理性与规范性。结果共纳入病例467例。完全符合DUE标准的病例有327例,占70.0%;符合用药指征评价标准的病例有440例,占94.2%;符合用药过程评价标准的病例有347例,占74.3%;有临床疗效的病例有453例,占97.0%;发生不良反应的病例有41例,占8.8%。结论建立重组人脑利钠肽DUE标准,可促进药物利用评价工作的标准化和规范化,有助于提高临床合理用药水平。AIM To establish criteria for the drug utilization evaluation(DUE)of recombinant human brain natriuretic peptide drugs,to assess the rationality and standardization of their clinical use,and to provide a reference for clinical rational medication.METHODS The DUE criteria of recombinant human brain natriuretic peptide were established by referring to drug instructions,related guidelines and expert consensus.Evaluated the rationality and standardization of recombinant human brain natriuretic peptide usage from September 2022 to November 2022 in the hospital,based on the established DUE criteria.RESULTS A total of 467 patients were included.There were 327 patients(70.0%)fully met the DUE evaluation criteria,440 patients(94.2%)met the evaluation criteria of drug indications,347 patients(74.3%)met the evaluation criteria of the medication process,453 patients(97.0%)showed clinical efficacy,and 41 patients(8.8%)experienced adverse reactions.CONCLUSION The establishment of DUE criteria for recombinant human brain natriuretic peptide can promote the standardization and normalization of drug utilization evaluation efforts,and help to improve the level of clinical rational medication.

关 键 词：重组人脑利钠肽 药物利用评价标准 合理用药 

分 类 号：R95[医药卫生—药学]